-
Something wrong with this record ?
Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives
M. Holecek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
ProQuest Central
from 1999-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-03-01 to 1 year ago
Health & Medicine (ProQuest)
from 1999-01-01 to 1 year ago
Psychology Database (ProQuest)
from 1999-01-01 to 1 year ago
- MeSH
- Ammonia metabolism MeSH
- Enterocytes metabolism MeSH
- Phenylbutyrates adverse effects pharmacology therapeutic use MeSH
- Glutamine metabolism MeSH
- Glutaminase antagonists & inhibitors MeSH
- Hyperammonemia drug therapy etiology metabolism MeSH
- Hepatic Encephalopathy diet therapy drug therapy metabolism MeSH
- Liver metabolism MeSH
- Muscle, Skeletal metabolism MeSH
- Critical Illness MeSH
- Glutamic Acid metabolism pharmacology therapeutic use MeSH
- Ketoglutaric Acids adverse effects pharmacology therapeutic use MeSH
- Kidney metabolism MeSH
- Drug Interactions MeSH
- Humans MeSH
- Microbiota MeSH
- Brain metabolism MeSH
- Organ Specificity MeSH
- Intestines microbiology MeSH
- Amino Acids, Branched-Chain metabolism therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
There is substantial clinical and experimental evidence that ammonia is a major factor in the pathogenesis of hepatic encephalopathy. In the article is demonstrated that in hepatocellular dysfunction, ammonia detoxification to glutamine (GLN) in skeletal muscle, brain, and likely the lungs, is activated. In addition to ammonia detoxification, enhanced GLN production may exert beneficial effects on the immune system and gut barrier function. However, enhanced GLN synthesis may exert adverse effects in the brain (swelling of astrocytes or altered neurotransmission) and stimulate catabolism of branched-chain amino acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle. Furthermore, the majority of GLN produced is released to the blood and catabolized in enterocytes and the kidneys to ammonia, which due to liver injury escapes detoxification to urea and appears in peripheral blood. As only one molecule of ammonia is detoxified in GLN synthesis whereas two molecules may appear in GLN breakdown, these events can be seen as a vicious cycle in which enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and increase in ammonia levels in the blood. These alterations may explain why therapies targeted to intestinal bacteria have only a limited effect on ammonia levels in patients with liver failure and indicate the needs of new therapeutic strategies focused on GLN metabolism. It is demonstrated that each of the various treatment options targeting only one the of the ammonia-lowering mechanisms that affect GLN metabolism, such as enhancing GLN synthesis (BCAA), suppressing ammonia production from GLN breakdown (glutaminase inhibitors and alpha-ketoglutarate), and promoting GLN elimination (phenylbutyrate) exerts substantial adverse effects that can be avoided if their combination is tailored to the specific needs of each patient.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023634
- 003
- CZ-PrNML
- 005
- 20150729100847.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11011-013-9428-9 $2 doi
- 035 __
- $a (PubMed)23996300
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Holecek, Milan $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Simkova 870, 500 38, Hradec Kralove, Czech Republic, holecek@lfhk.cuni.cz.
- 245 10
- $a Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives / $c M. Holecek,
- 520 9_
- $a There is substantial clinical and experimental evidence that ammonia is a major factor in the pathogenesis of hepatic encephalopathy. In the article is demonstrated that in hepatocellular dysfunction, ammonia detoxification to glutamine (GLN) in skeletal muscle, brain, and likely the lungs, is activated. In addition to ammonia detoxification, enhanced GLN production may exert beneficial effects on the immune system and gut barrier function. However, enhanced GLN synthesis may exert adverse effects in the brain (swelling of astrocytes or altered neurotransmission) and stimulate catabolism of branched-chain amino acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle. Furthermore, the majority of GLN produced is released to the blood and catabolized in enterocytes and the kidneys to ammonia, which due to liver injury escapes detoxification to urea and appears in peripheral blood. As only one molecule of ammonia is detoxified in GLN synthesis whereas two molecules may appear in GLN breakdown, these events can be seen as a vicious cycle in which enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and increase in ammonia levels in the blood. These alterations may explain why therapies targeted to intestinal bacteria have only a limited effect on ammonia levels in patients with liver failure and indicate the needs of new therapeutic strategies focused on GLN metabolism. It is demonstrated that each of the various treatment options targeting only one the of the ammonia-lowering mechanisms that affect GLN metabolism, such as enhancing GLN synthesis (BCAA), suppressing ammonia production from GLN breakdown (glutaminase inhibitors and alpha-ketoglutarate), and promoting GLN elimination (phenylbutyrate) exerts substantial adverse effects that can be avoided if their combination is tailored to the specific needs of each patient.
- 650 _2
- $a větvené aminokyseliny $x metabolismus $x terapeutické užití $7 D000597
- 650 _2
- $a amoniak $x metabolismus $7 D000641
- 650 _2
- $a mozek $x metabolismus $7 D001921
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a enterocyty $x metabolismus $7 D020895
- 650 _2
- $a kyselina glutamová $x metabolismus $x farmakologie $x terapeutické užití $7 D018698
- 650 _2
- $a glutaminasa $x antagonisté a inhibitory $7 D005972
- 650 _2
- $a glutamin $x metabolismus $7 D005973
- 650 _2
- $a jaterní encefalopatie $x dietoterapie $x farmakoterapie $x metabolismus $7 D006501
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperamonemie $x farmakoterapie $x etiologie $x metabolismus $7 D022124
- 650 _2
- $a střeva $x mikrobiologie $7 D007422
- 650 _2
- $a kyseliny ketoglutarové $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D007656
- 650 _2
- $a ledviny $x metabolismus $7 D007668
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a mikrobiota $7 D064307
- 650 _2
- $a kosterní svaly $x metabolismus $7 D018482
- 650 _2
- $a orgánová specificita $7 D009928
- 650 _2
- $a fenylbutyráty $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D010654
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00007770 $t Metabolic brain disease $x 1573-7365 $g Roč. 29, č. 1 (2014), s. 9-17
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23996300 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150729100933 $b ABA008
- 999 __
- $a ok $b bmc $g 1083971 $s 906627
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 29 $c 1 $d 9-17 $i 1573-7365 $m Metabolic brain disease $n Metab Brain Dis $x MED00007770
- LZP __
- $a Pubmed-20150709